Previsioni di mercato degli adiuvanti per vaccini nell\'Asia Pacifica fino al 2030 – Analisi regionale – per classe di adiuvanti (adiuvante di sale minerale, adiuvante di emulsione, adiuvante di liposomi e altri) e tipo (adiuvante di vaccino umano e adiuvante di vaccino veterinario)
I progressi in biotecnologia e immunologia potenziano il mercato degli adiuvanti per vaccini dell\'Asia Pacifica
Il mercato degli adiuvanti per vaccini presenta opportunità significative a causa della crescente domanda di una maggiore efficacia dei vaccini e dell\'espansione delle applicazioni dei vaccini oltre le tradizionali malattie infettive. Con l\'emergere di nuovi patogeni e l\'evoluzione di quelli esistenti, aumenta la necessità di adiuvanti in grado di potenziare le risposte immunitarie e fornire una protezione più ampia. I progressi in biotecnologia e immunologia stanno guidando l\'innovazione nelle formulazioni degli adiuvanti, offrendo nuove soluzioni per vaccini sia preventivi che terapeutici. Inoltre, l\'aumento dei programmi di vaccinazione globali e l\'aumento dei finanziamenti per la ricerca sui vaccini stanno alimentando la crescita del mercato. Le aziende che si concentrano sullo sviluppo di adiuvanti con profili di sicurezza migliorati e maggiore efficacia sono ben posizionate per capitalizzare questo mercato in espansione. Partnership e collaborazioni strategiche con istituti di ricerca e aziende biotecnologiche possono migliorare ulteriormente le opportunità in questo campo dinamico, rendendolo un\'area promettente per investimenti e sviluppo.
Panoramica del mercato degli adiuvanti per vaccini nell\'Asia Pacifica
Il mercato degli adiuvanti per vaccini nell\'Asia Pacifica è stato segmentato in Cina, Giappone, India, Australia, Corea del Sud e resto dell\'Asia Pacifica. Iniziative strategiche, come le collaborazioni tra aziende cinesi per produrre vaccini adiuvanti, guidano il mercato. Ad esempio, nell\'aprile 2020, Dynavax Technologies Corporation ha annunciato una collaborazione con la società biofarmaceutica cinese Sinovac per sviluppare l\'adiuvante CpG 1018. CpG 1018 è l\'adiuvante utilizzato in HEPLISAV-B [vaccino contro l\'epatite B (ricombinante), adiuvato], un vaccino contro l\'epatite B negli adulti approvato dalla Food and Drug Administration (FDA) statunitense per aumentare la risposta immunitaria al vaccino. Pertanto, sviluppi strategici come la collaborazione e le partnership da parte dei produttori cinesi per l\'approvvigionamento di vaccini adiuvati sono un fattore autonomo responsabile della crescita positiva del mercato.
Fatturato e previsioni del mercato degli adiuvanti per vaccini nell\'Asia Pacifica fino al 2030 (milioni di $ USA)
Segmentazione del mercato degli adiuvanti per vaccini nell\'Asia Pacifica
Il mercato degli adiuvanti per vaccini nell\'Asia Pacifica è suddiviso in classe, tipo e paese di adiuvanti.
In base alla classe di adiuvanti, il mercato degli adiuvanti per vaccini nell\'Asia Pacifica è suddiviso in adiuvante di sali minerali, adiuvante di emulsione, adiuvante di liposomi e altri. Il segmento degli adiuvanti dei sali minerali ha detenuto la quota maggiore del mercato degli adiuvanti dei vaccini dell\'Asia Pacifico nel 2022.
Per tipologia, il mercato degli adiuvanti dei vaccini dell\'Asia Pacifico è diviso in adiuvanti dei vaccini umani e adiuvanti dei vaccini veterinari. Il segmento degli adiuvanti dei vaccini umani ha detenuto una quota maggiore del mercato degli adiuvanti dei vaccini dell\'Asia Pacifico nel 2022.
Per paese, il mercato degli adiuvanti dei vaccini dell\'Asia Pacifico è suddiviso in Cina, Giappone, India, Australia, Corea del Sud e resto dell\'Asia Pacifico. La Cina ha dominato la quota di mercato degli adiuvanti dei vaccini dell\'Asia Pacifico nel 2022.
Croda International Plc; CSL Ltd; GSK Plc; Hawaii Biotech Inc; InvivoGen SAS; Novavax Inc; Phibro Animal Health Corp; e SPI Pharma Inc sono alcune delle aziende leader che operano nel mercato degli adiuvanti dei vaccini dell\'Asia Pacifico.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Vaccine Adjuvants Market – Key Market Dynamics
4.1 Asia Pacific Vaccine Adjuvants Market – Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
4.2.2 Approvals of Veterinary Vaccine Adjuvants
4.3 Market Restraints
4.3.1 Product Recalls and Adverse Effects
4.4 Market Opportunity
4.4.1 Advancements in Biotechnology and Immunology
4.5 Future Trends
4.5.1 Technological Advancements
4.6 Impact of Drivers and Restraints:
5. Vaccine Adjuvants Market –Asia Pacific Market Analysis
5.1 Asia Pacific Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
5.2 Asia Pacific Vaccine Adjuvants Market Forecast and Analysis
6. Asia Pacific Vaccine Adjuvants Market Analysis – by Adjuvant Class
6.1 Overview
6.2 Mineral Salt Adjuvant
6.2.1 Overview
6.2.2 Mineral Salt Adjuvant: Asia Pacific Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.3 Emulsion Adjuvant
6.3.1 Overview
6.3.2 Emulsion Adjuvant: Asia Pacific Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Liposome Adjuvant
6.4.1 Overview
6.4.2 Liposome Adjuvant: Asia Pacific Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: Asia Pacific Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Vaccine Adjuvants Market Analysis – by Type
7.1 Human Vaccine Adjuvant
7.1.1 Overview
7.1.2 Human Vaccine Adjuvant: Asia Pacific Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.2 Veterinary Vaccine Adjuvant
7.2.1 Overview
7.2.2 Veterinary Vaccine Adjuvant: Asia Pacific Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Vaccine Adjuvants Market –Country Analysis
8.1 Asia Pacific
8.1.1 Asia Pacific: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
8.1.1.1 China: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.1.1 Overview
8.1.1.1.2 China: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.1.3 China: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.1.4 China: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.2 Japan: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.2.1 Overview
8.1.1.2.2 Japan: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.2.3 Japan: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.2.4 Japan: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.3 India: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.3.1 Overview
8.1.1.3.2 India: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.3.3 India: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.3.4 India: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.4 Australia: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.4.1 Overview
8.1.1.4.2 Australia: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.4.3 Australia: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.4.4 Australia: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.5 South Korea: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.5.1 Overview
8.1.1.5.2 South Korea: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.5.3 South Korea: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.5.4 South Korea: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.6 Rest of APAC: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.6.1 Overview
8.1.1.6.2 Rest of APAC: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.6.3 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.6.4 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Type
9. Industry Landscape
9.1 Overview
9.2 Growth Strategies in the Vaccine Adjuvants Market
9.3 Organic Developments
9.3.1 Overview
9.4 Inorganic Developments
9.4.1 Overview
10. Company Profiles
10.1 SPI Pharma Inc
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 GSK Plc
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 CSL Ltd
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Hawaii Biotech Inc
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 InvivoGen SAS
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 Croda International Plc
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Novavax Inc
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Phibro Animal Health Corp
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
11. Appendix
11.1 About The Insight Partners
List of Tables
Table 1. Asia Pacific Vaccine Adjuvants Market Segmentation
Table 2. Asia Pacific Vaccine Adjuvants Market Revenue and Forecasts To 2030 (US$ Million)
Table 3. China: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 4. China: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 5. Japan: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 6. Japan: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 7. India: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 8. India: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 9. Australia: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 10. Australia: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 11. South Korea: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 12. South Korea: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 13. Rest of APAC: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 14. Rest of APAC: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 15. Organic Developments Done by Companies
Table 16. Inorganic Developments Done by Companies
List of Figures
Figure 1. Asia Pacific Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Asia Pacific Vaccine Adjuvants Market Revenue (US$ Million), 2022–2030
Figure 4. Asia Pacific Vaccine Adjuvants Market Share (%) – by Adjuvant Class (2022 and 2030)
Figure 5. Mineral Salt Adjuvant: Asia Pacific Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Asia Pacific Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Liposome Adjuvant: Asia Pacific Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Asia Pacific Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Asia Pacific Vaccine Adjuvants Market Share (%) – by Type (2022 and 2030)
Figure 10. Human Vaccine Adjuvant: Asia Pacific Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Veterinary Vaccine Adjuvant: Asia Pacific Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Asia Pacific: Vaccine Adjuvants Market – Revenue by Key Countries 2022 (US$ Million)
Figure 13. Asia Pacific: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 14. China: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 15. Japan: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 16. India: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 17. Australia: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 18. South Korea: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 19. Rest of APAC: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 20. Growth Strategies in the Vaccine Adjuvants Market
- Croda International Plc
- CSL Ltd
- GSK Plc
- Hawaii Biotech Inc
- InvivoGen SAS
- Novavax Inc
- Phibro Animal Health Corp
- SPI Pharma Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific vaccine adjuvants market.
- Highlights key business priorities to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific vaccine adjuvants market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.